The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Open accessAbstract
Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in improving overall survival of several malignancies associated with poor outcomes; however, only 20-40% of patients will show long-lasting survival. Further clarification of factors related to treatment response can support improvements in clinical outcome and guide the development of novel immune checkpoint therapies. In this article, we have provided an overview of the pharmacokinetic (PK) aspects related to current ICIs, which include target-mediated drug disposition and time-varying drug clearance. In response to the variation in treatment exposure of ICIs and the significant healthcare costs associated with these agents, arguments for both dose individualization and generalization are provided. We address important issues related to the efficacy and safety, the pharmacodynamics (PD), of ICIs, including exposure-response relationships related to clinical outcome. The unique PK and PD aspects of ICIs give rise to issues of confounding and suboptimal surrogate endpoints that complicate interpretation of exposure-response analysis. Biomarkers to identify patients benefiting from treatment with ICIs have been brought forward. However, validated biomarkers to monitor treatment response are currently lacking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 939
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
Pharmacokinetics of Monoclonal Antibodies
Ryman, J. T., & Meibohm, B. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12224 · Cited by 802
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1761 · Cited by 594
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Understanding cachexia as a cancer metabolism syndrome
Porporato, P. E. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.3 · Cited by 562
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
Improved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R., Anderson, A., Humphrey, R., Blumenstein, B., Old, L., & Wolchok, J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 518
De Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., Schutz, F., Bellmunt, J., Sonpavde, G. P., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0237 · Cited by 486
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382
At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
Pillai, R. N., Behera, M., Owonikoko, T. K., Kamphorst, A. O., Pakkala, S., Belani, C. P., Khuri, F. R., Ahmed, R., & Ramalingam, S. S. (2018) · Cancer · doi:10.1002/cncr.31043 · Cited by 330
Sharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
Gulley, J. L., Rajan, A., Spigel, D. R., Iannotti, N., Chandler, J., Wong, D. J. L., Leach, J., Edenfield, W. J., Wang, D., Grote, H. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30240-1 · Cited by 286
Evaluation of dosing strategy for pembrolizumab for oncology indications
Freshwater, T., Kondic, A., Ahamadi, M., Li, C. H., de Greef, R., de Alwis, D., & Stone, J. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0242-5 · Cited by 267
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Bajaj, G., Wang, X., Agrawal, S., Gupta, M., Roy, A., & Feng, Y. (2017) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12143 · Cited by 264
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Du, X., Tang, F., Liu, M., Su, J., Zhang, Y., Wu, W., Devenport, M., Lazarski, C. A., Zhang, P., Wang, X., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0011-0 · Cited by 249
Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx235 · Cited by 244
Schneider-Merck, T., Lammerts van Bueren, J. J., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 222
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Agrawal, S., Feng, Y., Roy, A., Kollia, G., & Lestini, B. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0177-2 · Cited by 222
Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3704 · Cited by 221
Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G., Garon, E. B., Riess, J. W., Jain, L., Mayawala, K., Kang, J., Ebbinghaus, S. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0415 · Cited by 217
Liu, C., Yu, J., Li, H., Liu, J., Xu, Y., Song, P., Liu, Q., Zhao, H., Xu, J., Maher, V., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.656 · Cited by 198
Feng, Y., Roy, A., Masson, E., Chen, T.-T., Humphrey, R., & Weber, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3243 · Cited by 183
MacFarlane, A. W., Jillab, M., Plimack, E. R., Hudes, G. R., Uzzo, R. G., Litwin, S., Dulaimi, E., Al-Saleem, T., & Campbell, K. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0133 · Cited by 177
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Chatterjee, M., Turner, D. C., Felip, E., Lena, H., Cappuzzo, F., Horn, L., Garon, E. B., Hui, R., Arkenau, H.-T., Gubens, M. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw174 · Cited by 172
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 170
Durvalumab: First Global Approval
Syed, Y. Y. (2017) · Drugs · doi:10.1007/s40265-017-0782-5 · Cited by 170
Fixed Dosing of Monoclonal Antibodies in Oncology
Hendrikx, J. J. M. A., Haanen, J. B. A. G., Voest, E. E., Schellens, J. H. M., Huitema, A. D. R., & Beijnen, J. H. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0167 · Cited by 168
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
Villaruz, L. C., & Socinski, M. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2935 · Cited by 165
Ahamadi, M., Freshwater, T., Prohn, M., Li, C. H., de Alwis, D., de Greef, R., Elassaiss‐Schaap, J., Kondic, A. G., & Stone, J. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12139 · Cited by 165
Tang, F., & Zheng, P. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0232-4 · Cited by 164
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma
Stroh, M., Winter, H. R., Marchand, M., Claret, L., Eppler, S., Ruppel, J., Abidoye, O. O., Teng, S., Lin, W., Dayog, S., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.587 · Cited by 163
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
van Brummelen, E. M. J., Ros, W., Wolbink, G., Beijnen, J. H., & Schellens, J. H. M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0061 · Cited by 158
Baverel, P., Dubois, V. F. S., Jin, C. Y., Zheng, Y., Song, X., Jin, X., Mukhopadhyay, P., Gupta, A. K., Dennis, P. A., Ben, Y., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.982 · Cited by 156
Li, H., Yu, J., Liu, C., Liu, J., Subramaniam, S., Zhao, H., Blumenthal, G. M., Turner, D. C., Li, C. H., Ahamadi, M., et al. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9528-y · Cited by 150
Treating with Checkpoint Inhibitors-Figure $1 Million per Patient.
Andrews, A. (2015) · PubMed · Cited by 126
Ryan, É., Sheahan, K., Creavin, B., Mohan, H., & Winter, D. (2017) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2017.05.006 · Cited by 126
Influence of immunoglobulin isotype on therapeutic antibody function
Beers, S. A., Glennie, M. J., & White, A. L. (2016) · Blood · doi:10.1182/blood-2015-09-625343 · Cited by 125
Elassaiss‐Schaap, J., Rossenu, S., Lindauer, A., Kang, S., de Greef, R., Sachs, J., & de Alwis, D. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12132 · Cited by 124
Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
Ibrahim, R. A., Berman, D. M., DePril, V., Humphrey, R. W., Chen, T., MESSINA, M. E., Chin, K. M., Liu, H. Y., Bielefield, M., & Hoos, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8583 · Cited by 123
Gibiansky, L. V., & Gibiansky, E. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902992901 · Cited by 116
Model‐based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
Feng, Y., Masson, E., Dai, D., Parker, S. M., Berman, D., & Roy, A. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12323 · Cited by 115
Systems Pharmacology: Defining the Interactions of Drug Combinations
van Hasselt, J. G. C., & Iyengar, R. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021511 · Cited by 110
Evolution of end points for cancer immunotherapy trials
Hoos, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds263 · Cited by 103
Munnink, T. H. O., Henstra, M. J., Segerink, L., Movig, K. L. L., & Brummelhuis-Visser, P. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.211 · Cited by 99
Venkatakrishnan, K., Friberg, L. E., Ouellet, D., Mettetal, J. T., Stein, A. M., Trocóniz, I. F., Bruno, R., Mehrotra, N., Gobburu, J. V. S., & Mould, D. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.7 · Cited by 97
Self-citationBartelink, I. H., Jones, E. F., Shahidi‐Latham, S. K., Lee, P. R. E., Zheng, Y., Vicini, P., van ‘t Veer, L., Wolf, D., Iagaru, A., Kroetz, D. L., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1211 · Cited by 96
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
Eroglu, Z., Kim, D. W., Wang, X., Camacho, L. H., Chmielowski, B., Seja, E., Villanueva, A., Ruchalski, K. L., Glaspy, J. A., Kim, K. B., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.012 · Cited by 93
Wang, X., Feng, Y.-Y., Bajaj, G., Gupta, M., Agrawal, S., Yang, A., Park, J.-S., Lestini, B. J., & Roy, A. K. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12133 · Cited by 91
Donahue, R. N., Lepone, L. M., Grenga, I., Jochéms, C., Fantini, M. C., Madan, R. A., Heery, C. R., Gulley, J. L., & Schlom, J. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0220-y · Cited by 91
Chatterjee, M., Elassaiss‐Schaap, J., Lindauer, A., Turner, D., Sostelly, A., Freshwater, T., Mayawala, K., Ahamadi, M., Stone, J., de Greef, R., et al. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12140 · Cited by 89
Waki, K., Yamada, T., Yoshiyama, K., Terazaki, Y., Sakamoto, S., Matsueda, S., Komatsu, N., Sugawara, S., Takamori, S., Itoh, K., et al. (2014) · Cancer Science · doi:10.1111/cas.12502 · Cited by 84
Antibody Isotypes for Tumor Immunotherapy
Kretschmer, A., Schwanbeck, R., Valerius, T., & Rösner, T. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479240 · Cited by 82
Ribba, B., Boetsch, C., Nayak, T. K., Grimm, H. P., Charo, J., Evers, S., Klein, C., Tessier, J. J. L., Charoin, J. E., Phipps, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2953 · Cited by 77
Implications for Clinical Practice and Trial Design
Oeberg, K. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32691-0 · Cited by 74
Shukuya, T., Mori, K. P., Amann, J. M., Bertino, E. M., Otterson, G. A., Shields, P. G., Morita, S., & Carbone, D. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.017 · Cited by 74
Ogungbenro, K., Patel, A., Duncombe, R., Nuttall, R., Clark, J., & Lorigan, P. C. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.875 · Cited by 72
Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
Basak, E. A., Koolen, S. L. W., Hurkmans, D. P., Schreurs, M. W. J., Bins, S., Hoop, E. O., Wijkhuijs, A. J. M., den Besten, I., Sleijfer, S., Debets, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.008 · Cited by 72
Caulet, M., Lecomte, T., Bouché, O., Rollin, J., Gouilleux‐Gruart, V., Azzopardi, N., Léger, J., Borg, C., Douillard, J., Manfrédi, S., et al. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0406-3 · Cited by 69
Time Is Money: Optimizing the Scheduling of Nivolumab
Ratain, M. J., & Goldstein, D. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00045 · Cited by 67
Bécher, F., Ciccolini, J., Imbs, D.-C., Marin, C., Fournel, C., Dupuis, C., Fakhry, N., Pourroy, B., Ghettas, A., Pruvost, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02821-x · Cited by 60
Self-citationApproved checkpoint inhibitors in bladder cancer: which drug should be used when?
Ghatalia, P., Zibelman, M. R., Geynisman, D. M., & Plimack, E. R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918788310 · Cited by 58
Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats
Tawara, T., Hasegawa, K., Sugiura, Y., Harada, K., Miura, T., Hayashi, S., Tahara, T., Ishikawa, M., Yoshida, H., Kubo, K., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2294 · Cited by 56
Towards integrative systems pharmacology models in oncology drug development
van Hasselt, J. G. C., & van der Graaf, P. H. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.06.004 · Cited by 36
Abuqayyas, L., & Balthasar, J. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.042 · Cited by 35
Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer
Pointreau, Y., Azzopardi, N., Ternant, D., Calais, G., & Paintaud, G. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000321 · Cited by 33
Optimizing drug development of anti‐cancer drugs in children using modelling and simulation
van Hasselt, J. G. C., van Eijkelenburg, N. K. A., Beijnen, J. H., Schellens, J. H. M., & Huitema, A. D. R. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12062 · Cited by 29
van Hasselt, J. G. C., Gupta, A., Hussein, Z., Beijnen, J. H., Schellens, J. H. M., & Huitema, A. D. R. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.49 · Cited by 22
Checkpoint inhibitors in H odgkin's lymphoma
Novaković, B. J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12697 · Cited by 14
van Vugt, M. J. H., de Greef, R., Freshwater, T., Mangin, E. C., van Aarle, F., & Kondic, A. G. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3063 · Cited by 12
Kaufman, H. L., Schwartz, L. H., William, W. N., Sznol, M., del Aguila, M., Whittington, C. J., Fahrbach, K. R., Xu, Y., Masson, E., Dempster, S. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e14557 · Cited by 11
The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing
Ruiz-Cerdá, L., Asín‐Prieto, E., Parra-Guillen, Z. P., & Trocóniz, I. F. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0580 · Cited by 7
Self-citationMotzer, R. J., Sharma, P., Escudier, B. J., McDermott, D. F., George, S., Srinivas, S., Tykodi, S. S., Sosman, J. A., Plimack, E. R., Nathan, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4552 · Cited by 6
Cited by
Safa, H., Johnson, D. H., Trinh, V. A., Rodgers, T. E., Lin, H., Suarez-Almazor, M. E., Fa’ak, F., Saberian, C., Yee, C., Davies, M. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0774-y · Cited by 312
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Lehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178
Raschi, E., Mazzarella, A., Antonazzo, I. C., Bendinelli, N., Forcesi, E., Tuccori, M., Moretti, U., Poluzzi, E., & De Ponti, F. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00632-w · Cited by 101
Shemesh, C. S., Chanu, P., Jamsen, K., Wada, R., Rossato, G., Donaldson, F., Garg, A., Winter, H., Ruppel, J., Wang, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0791-x · Cited by 43
Metadata
- Authors
- Centanni, M., Moes, D. J. A. R., Trocóniz, I. F., Ciccolini, J., & van Hasselt, J. G. C.
- Venue
- Clinical Pharmacokinetics
- Published
- 2019-02-28
- Volume
- 58
- Issue
- 7
- Pages
- 835-857
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2919428266
- Cited by
- 355
- References
- 101
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.